<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03086460</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-05993AA3-03</org_study_id>
    <nct_id>NCT03086460</nct_id>
  </id_info>
  <brief_title>A Dose Ranging Study of CHF 1531 in Asthmatic Subjects</brief_title>
  <acronym>FLASH</acronym>
  <official_title>A Randomized, Double-blind, Placebo and Active-controlled, Incomplete Block Cross-over, Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of CHF 1531 pMDI (Formoterol Fumarate) in Asthmatic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the dose-response of different doses of CHF 1531 on
      lung function and other clinical outcomes, to identify the optimal dose(s) in terms of
      benefit/ risk ratio for further development in the target subject population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, randomized, double-blind, placebo and active controlled dose-ranging, 6
      arm incomplete block cross-over study to identify the optimal dose of CHF 1531 with respect
      to lung function and other clinical efficacy and safety outcomes.

      After a 2 week run-in period under rescue albuterol as needed and background inhaled
      corticosteroid (ICS), qualifying subjects will be required to complete 4 treatment periods of
      2 weeks each separated by a 2 week wash-out intervals. During each treatment period, the
      subject will be randomly assigned to take one of 5 double-blind study treatments twice daily
      (one of 4 doses of CHF 1531 or a matching placebo) or the open-label active control treatment
      also twice daily. All subjects will concomitantly receive ICS treatment with QVAR® inhaler
      (beclomethasone dipropionate 40 or 80 µg /actuation) twice daily at a dose that matches their
      pre-enrollment ICS, and an albuterol inhaler to use as needed as asthma rescue medication,
      during the entire study. The subjects will visit the study center every 2 weeks to undergo
      study procedures, and will receive a safety follow-up phone call one week after their last
      visit. In total, the study will last 18 weeks and will require 10 visits to the study center.

      During the study, daily asthma symptoms, peak expiratory flow, rescue and background
      medication use, and compliance with the study medication will be recorded via subject diary.
      Treatment-Emergent Adverse Events (TEAEs) will be assessed and recorded throughout the study.
      A full physical exam, routine hematology, blood chemistry, spirometry, vital signs
      measurement, 12-lead ECG and pregnancy testing will be performed before enrollment and at end
      of study. Furthermore on Day 1 and 14 of each treatment period, serial spirometry, 12-lead
      ECGs, BP, and serum potassium and glucose will also be measured at the study center up to 12
      hours post-dosing.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 8, 2017</start_date>
  <completion_date type="Anticipated">July 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in FEV1 AUC0-12h normalized by time at Day 14</measure>
    <time_frame>14 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FEV1 AUC0-12h normalized by time at Day 1</measure>
    <time_frame>1 Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FEV1 AUC0-4h normalized by time and in FEV1 peak0-4h at Day 1 and Day 14</measure>
    <time_frame>1 Day &amp; 14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FVC AUC0-12h normalized by time, in FVC AUC0-4h normalized by time and in FVC peak0-4h at Day 1 and at Day 14</measure>
    <time_frame>1 Day &amp; 14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pre-dose morning FEV1 at Day 14</measure>
    <time_frame>14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pre-dose morning FVC at Day 14</measure>
    <time_frame>14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of action (change from baseline in post-dose FEV1 ≥ 12% and ≥ 200mL) at Day 1</measure>
    <time_frame>1 Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Drug Reactions (ADRs)</measure>
    <time_frame>14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs (systolic and diastolic blood pressure)</measure>
    <time_frame>14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECG parameters (HR, QTcF, QRS, PR)</measure>
    <time_frame>14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HR AUC0-4h normalized by time and HR peak0-4h</measure>
    <time_frame>14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum potassium and blood glucose</measure>
    <time_frame>14 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF 1531 pMDI Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF 1531 pMDI Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF 1531 pMDI Dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF 1531 pMDI Dose 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matched placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment F</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol fumarate inhalation solution, 20μg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 1531</intervention_name>
    <description>Dose Response: Test one of five different doses of CHF 1531</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
    <other_name>Dose Finding</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol Inhalation Solution</intervention_name>
    <description>Active Control</description>
    <arm_group_label>Treatment F</arm_group_label>
    <other_name>PERFOROMIST® 20μg/ 2mL vial, 1 vial bid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched Placebo</description>
    <arm_group_label>Treatment E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged ≥18 and ≤75 years who have signed an Informed Consent
             Form prior to initiation of any study-related procedure.

          -  A diagnosis of asthma as defined in the GINA Report, 2016, documented for at least 1
             year prior to screening.

          -  Poorly controlled or uncontrolled asthma evidenced by a score ≥1.5 on the Asthma
             Control Questionnaire 7 © (ACQ-7)

          -  A pre-bronchodilator FEV1 ≥60% and &lt;85% of their predicted normal value, after
             appropriate washout from bronchodilators, at the screening and randomization visits

          -  Subjects with a positive response to a reversibility test at screening, defined as
             ΔFEV1 ≥12% and ≥200mL over baseline within 30 minutes after inhaling 4 puffs of
             albuterol HFA 90µg/actuation.

          -  Use of ICS (low/medium dose according to GINA Report, 2016) with or without a LABD for
             3 months (at a stable dose in the last 4 weeks) before screening visit.

          -  A cooperative attitude and ability to demonstrate correct use of the diary, peak flow
             meter and pMDI inhaler.

        Exclusion Criteria:

          -  Pregnant or lactating women and all women physiologically capable of becoming pregnant
             UNLESS they are willing to use a highly effective birth control methods

          -  Subjects who suffer from COPD as defined by the GOLD Report, 2017, or are suspected of
             having Asthma COPD Overlap Syndrome (ACOS) as described in the GINA Report, 2016.

          -  Inability to carry out pulmonary function testing, to comply with study procedures or
             with study drug intake.

          -  Current smokers or ex-smokers (tobacco, vapor cigarettes, marijuana) with a smoking
             history of &gt;10 pack-years or having stopped smoking one year or less prior to
             screening visit.

          -  History of life-threatening asthma, clinically significant uncontrolled disease or
             respiratory infection.

          -  An asthma exacerbation requiring oral/intravenous corticosteroids ≤ 30 days,
             intramuscular depot corticosteroid ≤3 months or hospitalization within 6 months prior
             to screening.

          -  Subjects with unresolved bacterial or viral respiratory tract, sinus, or middle ear
             infection affecting asthma status within 2 weeks prior to screening.

          -  Subjects who received a vaccination within 2 weeks prior to screening or during the
             run-in.

          -  Subjects with oral candidiasis at screening and at randomization.

          -  Subjects with any clinically significant, uncontrolled condition.

          -  Subjects with serum potassium levels &lt;3.5 mEq/L (or 3.5 mmol/L) at screening.

          -  Subjects who have clinically significant cardiovascular condition.

          -  Subjects who have a clinically significant abnormal 12-lead ECG that results in active
             medical problem which may impact the safety of the patient according to Investigator's
             judgment.

          -  Subjects whose 12-lead ECG shows Fridericia's corrected QT interval (QTcF) &gt;450ms for
             males or QTcF &gt;470ms for females at screening or randomization visits.

          -  Subjects with known intolerance/hypersensitivity or contra-indication to treatment
             with inhaled β2-adrenergic receptor agonists, corticosteroids or propellant
             gases/excipients.

          -  Subjects with concomitant immunosuppressive therapy, use of oral or injected
             corticosteroids, anti-IgE, anti-IL5 or other monoclonal or polyclonal antibodies
             within 12 weeks prior to screening.

          -  Use of potent cytochrome P450 3A4 inhibitors and inducers within 4 weeks prior to
             screening.

          -  History of alcohol abuse and/or substance/drug abuse within 12 months prior to
             screening.

          -  Subjects who have received an investigational drug within 1 month or 5 half-lives
             (whichever is greater) prior to screening visit, or have been previously randomized in
             this trial, or are currently participating in another clinical trial.

          -  Subjects who are mentally or legally incapacitated or subjects accommodated in an
             establishment as a result of an official or judicial order.

          -  Subjects who have undergone major surgery in the 3 months prior to screening visit or
             have a planned surgery during the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Sterling</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sterling ENT, PA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Del Sol Research Management, LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Institute For Respiratory Diseases, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Allergy and Asthma Centers</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Research Center, LLC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitalink Research</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling ENT, PA</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Phase Research &amp; Development</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Columbia Research</name>
      <address>
        <city>Richland</city>
        <state>Washington</state>
        <zip>99352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://goldcopd.org/</url>
    <description>Global Initiative for Chronic Obstructive Lung Disease, Inc. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease: 2017</description>
  </link>
  <link>
    <url>http://www.ginasthma.org</url>
    <description>Global Initiative for Asthma. Global strategy for asthma management and prevention (2016 update). 2016.</description>
  </link>
  <link>
    <url>https://www.cdc.gov/asthma/most_recent_data.htm</url>
    <description>Centers for Disease Control and Prevention: Asthma</description>
  </link>
  <link>
    <url>http://www.chiesigroup.com/en/respiratory</url>
    <description>Chiesi Farmaceutici S.p.A Respiratory</description>
  </link>
  <link>
    <url>http://www.chiesigroup.com/en/chiesi-farmaceutici-is-the-first-company-to-submit-a-marketing-authorisation-application-to-the-european-medicine-agency-for-a-triple-combination-for-the-treatment-of-copd-</url>
    <description>Chiesi Farmaceutici S.p.A - Press Release: Chiesi Farmaceutifici is the first company to submit a marketing authorisation application to the European Medicine Agency for a triple combination for the treatment of COPD</description>
  </link>
  <link>
    <url>http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/724/foradil-aerolizer-formoterol-fumarate-inhalation-powder</url>
    <description>CenterWatch: Foradil Aerolizer (formoterol fumarate inhalation powder)</description>
  </link>
  <link>
    <url>http://www.rtmagazine.com/2015/10/asthma-copd-foradil-aerolizer-to-be-discontinued/</url>
    <description>RT Magazine: Asthma-COPD Therapy Foradil Aerolizer to be Discontinued</description>
  </link>
  <link>
    <url>https://www.drugs.com/history/perforomist.html</url>
    <description>Drugs.com: Perforomist Approval History</description>
  </link>
  <reference>
    <citation>Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2095-128. doi: 10.1016/S0140-6736(12)61728-0. Erratum in: Lancet. 2013 Feb 23;381(9867):628. AlMazroa, Mohammad A [added]; Memish, Ziad A [added].</citation>
    <PMID>23245604</PMID>
  </reference>
  <reference>
    <citation>Tilert T, Dillon C, Paulose-Ram R, Hnizdo E, Doney B. Estimating the U.S. prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007-2010. Respir Res. 2013 Oct 9;14:103. doi: 10.1186/1465-9921-14-103.</citation>
    <PMID>24107140</PMID>
  </reference>
  <reference>
    <citation>Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002 May;121(5 Suppl):121S-126S. Review.</citation>
    <PMID>12010839</PMID>
  </reference>
  <reference>
    <citation>Tønnesen P. Smoking cessation and COPD. Eur Respir Rev. 2013 Mar 1;22(127):37-43. doi: 10.1183/09059180.00007212. Review.</citation>
    <PMID>23457163</PMID>
  </reference>
  <reference>
    <citation>van Eerd EA, van der Meer RM, van Schayck OC, Kotz D. Smoking cessation for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016 Aug 20;(8):CD010744. doi: 10.1002/14651858.CD010744.pub2. Review.</citation>
    <PMID>27545342</PMID>
  </reference>
  <reference>
    <citation>Kew KM, Mavergames C, Walters JA. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013 Oct 15;(10):CD010177. doi: 10.1002/14651858.CD010177.pub2. Review.</citation>
    <PMID>24127118</PMID>
  </reference>
  <reference>
    <citation>McGarvey L, Niewoehner D, Magder S, Sachs P, Tetzlaff K, Hamilton A, Korducki L, Bothner U, Vogelmeier C, Koch A, Ferguson GT. One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis. COPD. 2015;12(5):484-93. doi: 10.3109/15412555.2014.991864. Epub 2015 Feb 18.</citation>
    <PMID>25692310</PMID>
  </reference>
  <reference>
    <citation>Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010 Jun;65(6):473-9. doi: 10.1136/thx.2009.125435.</citation>
    <PMID>20522841</PMID>
  </reference>
  <reference>
    <citation>Keating GM. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. Drugs. 2012 Jan 22;72(2):273-300. doi: 10.2165/11208620-000000000-00000. Review.</citation>
    <PMID>22217233</PMID>
  </reference>
  <reference>
    <citation>Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005 Mar;127(3):809-17.</citation>
    <PMID>15764761</PMID>
  </reference>
  <reference>
    <citation>Kesten S, Casaburi R, Kukafka D, Cooper CB. Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis. 2008;3(1):127-36.</citation>
    <PMID>18488436</PMID>
  </reference>
  <reference>
    <citation>Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Jul 11;(7):CD009285. doi: 10.1002/14651858.CD009285.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;(7):CD009285.</citation>
    <PMID>22786525</PMID>
  </reference>
  <reference>
    <citation>Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15.</citation>
    <PMID>27181606</PMID>
  </reference>
  <reference>
    <citation>Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Jul 11;(7):CD002991. doi: 10.1002/14651858.CD002991.pub3. Review.</citation>
    <PMID>22786484</PMID>
  </reference>
  <reference>
    <citation>Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014 Mar 10;(3):CD010115. doi: 10.1002/14651858.CD010115.pub2. Review.</citation>
    <PMID>24615270</PMID>
  </reference>
  <reference>
    <citation>Yawn BP, Li Y, Tian H, Zhang J, Arcona S, Kahler KH. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis. 2013;8:295-304. doi: 10.2147/COPD.S42366. Epub 2013 Jun 27.</citation>
    <PMID>23836970</PMID>
  </reference>
  <reference>
    <citation>Rachelefsky GS, Liao Y, Faruqi R. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis. Ann Allergy Asthma Immunol. 2007 Mar;98(3):225-38.</citation>
    <PMID>17378253</PMID>
  </reference>
  <reference>
    <citation>Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004 Jul;126(1):213-9. Review.</citation>
    <PMID>15249465</PMID>
  </reference>
  <reference>
    <citation>Tashkin DP, Murray HE, Skeans M, Murray RP. Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II. Chest. 2004 Oct;126(4):1123-33.</citation>
    <PMID>15486373</PMID>
  </reference>
  <reference>
    <citation>Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009 Sep;34(3):641-7. doi: 10.1183/09031936.00193908. Epub 2009 May 14.</citation>
    <PMID>19443528</PMID>
  </reference>
  <reference>
    <citation>Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Lettis S, Calverley PM. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015 Jan;12(1):27-34. doi: 10.1513/AnnalsATS.201409-413OC.</citation>
    <PMID>25490706</PMID>
  </reference>
  <reference>
    <citation>Pavord ID, Lettis S, Anzueto A, Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med. 2016 Sep;4(9):731-741. doi: 10.1016/S2213-2600(16)30148-5. Epub 2016 Jul 23.</citation>
    <PMID>27460163</PMID>
  </reference>
  <reference>
    <citation>Johnell O, Pauwels R, Löfdahl CG, Laitinen LA, Postma DS, Pride NB, Ohlsson SV. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J. 2002 Jun;19(6):1058-63.</citation>
    <PMID>12108857</PMID>
  </reference>
  <reference>
    <citation>Ferguson GT, Calverley PMA, Anderson JA, Jenkins CR, Jones PW, Willits LR, Yates JC, Vestbo J, Celli B. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest. 2009 Dec;136(6):1456-1465. doi: 10.1378/chest.08-3016. Epub 2009 Jul 6.</citation>
    <PMID>19581353</PMID>
  </reference>
  <reference>
    <citation>Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011 Aug;66(8):699-708. doi: 10.1136/thx.2011.160028. Epub 2011 May 20. Review.</citation>
    <PMID>21602540</PMID>
  </reference>
  <reference>
    <citation>Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010 Nov;123(11):1001-6. doi: 10.1016/j.amjmed.2010.06.019. Epub 2010 Oct 1.</citation>
    <PMID>20870201</PMID>
  </reference>
  <reference>
    <citation>Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology. 2009 Apr;116(4):652-7. doi: 10.1016/j.ophtha.2008.12.001. Epub 2009 Feb 25.</citation>
    <PMID>19243828</PMID>
  </reference>
  <reference>
    <citation>Miller DP, Watkins SE, Sampson T, Davis KJ. Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database. Int J Chron Obstruct Pulmon Dis. 2011;6:467-76. doi: 10.2147/COPD.S14247. Epub 2011 Sep 16.</citation>
    <PMID>22003292</PMID>
  </reference>
  <reference>
    <citation>Andréjak C, Nielsen R, Thomsen VØ, Duhaut P, Sørensen HT, Thomsen RW. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013 Mar;68(3):256-62. doi: 10.1136/thoraxjnl-2012-201772. Epub 2012 Jul 10.</citation>
    <PMID>22781123</PMID>
  </reference>
  <reference>
    <citation>Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007 Apr 17;146(8):545-55. Epub 2007 Feb 19.</citation>
    <PMID>17310045</PMID>
  </reference>
  <reference>
    <citation>Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of &quot;triple&quot; therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008 Jul;63(7):592-8. doi: 10.1136/thx.2007.087213. Epub 2008 Feb 1.</citation>
    <PMID>18245142</PMID>
  </reference>
  <reference>
    <citation>Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012 Jan;106(1):91-101. doi: 10.1016/j.rmed.2011.09.002. Epub 2011 Oct 29.</citation>
    <PMID>22040533</PMID>
  </reference>
  <reference>
    <citation>Frith PA, Thompson PJ, Ratnavadivel R, Chang CL, Bremner P, Day P, Frenzel C, Kurstjens N; Glisten Study Group. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax. 2015 Jun;70(6):519-27. doi: 10.1136/thoraxjnl-2014-206670. Epub 2015 Apr 3.</citation>
    <PMID>25841237</PMID>
  </reference>
  <reference>
    <citation>Siler TM, Kerwin E, Singletary K, Brooks J, Church A. Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies. COPD. 2016;13(1):1-10. doi: 10.3109/15412555.2015.1034256. Epub 2015 Oct 9.</citation>
    <PMID>26451734</PMID>
  </reference>
  <reference>
    <citation>Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016 Sep 3;388(10048):963-73. doi: 10.1016/S0140-6736(16)31354-X. Epub 2016 Sep 1.</citation>
    <PMID>27598678</PMID>
  </reference>
  <reference>
    <citation>Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006 Jan;129(1):15-26. Erratum in: Chest. 2006 May;129(5):1393.</citation>
    <PMID>16424409</PMID>
  </reference>
  <reference>
    <citation>Wijesinghe M, Weatherall M, Perrin K, Harwood M, Beasley R. Risk of mortality associated with formoterol: a systematic review and meta-analysis. Eur Respir J. 2009 Oct;34(4):803-11. doi: 10.1183/09031936.00159708. Review.</citation>
    <PMID>19797669</PMID>
  </reference>
  <reference>
    <citation>Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med. 2010 Apr 1;362(13):1169-71. doi: 10.1056/NEJMp1002074. Epub 2010 Feb 24.</citation>
    <PMID>20181964</PMID>
  </reference>
  <reference>
    <citation>Drazen JM, O'Byrne PM. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med. 2009 Apr 16;360(16):1671-2. doi: 10.1056/NEJMe0902057.</citation>
    <PMID>19369675</PMID>
  </reference>
  <reference>
    <citation>Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N Engl J Med. 2011 Jun 30;364(26):2473-5. doi: 10.1056/NEJMp1104375.</citation>
    <PMID>21714647</PMID>
  </reference>
  <reference>
    <citation>Stempel DA, Raphiou IH, Kral KM, Yeakey AM, Emmett AH, Prazma CM, Buaron KS, Pascoe SJ; AUSTRI Investigators. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone. N Engl J Med. 2016 May 12;374(19):1822-30. doi: 10.1056/NEJMoa1511049. Epub 2016 Mar 6.</citation>
    <PMID>26949137</PMID>
  </reference>
  <reference>
    <citation>Stempel DA, Szefler SJ, Pedersen S, Zeiger RS, Yeakey AM, Lee LA, Liu AH, Mitchell H, Kral KM, Raphiou IH, Prillaman BA, Buaron KS, Yun Kirby S, Pascoe SJ; VESTRI Investigators. Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. N Engl J Med. 2016 Sep 1;375(9):840-9. doi: 10.1056/NEJMoa1606356.</citation>
    <PMID>27579634</PMID>
  </reference>
  <reference>
    <citation>Novartis Pharma. FORADIL®AEROLIZER® US Prescribing Information. Whitehouse Station, New Jersey; 2012 Sep.</citation>
  </reference>
  <reference>
    <citation>Bousquet J, Huchon G, Leclerc V, Vicaut E, Lefrançois G. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients. Respiration. 2005;72 Suppl 1:6-12.</citation>
    <PMID>15915007</PMID>
  </reference>
  <reference>
    <citation>Chiesi Farmaceutici S.p.A. A randomized, double blind, double dummy, single dose, crossover trial comparing the efficacy and safety of a single dose administered via 1 puff of 6 μg or 2 puffs of 6 μg of formoterol-HFA (pMDI) versus a single dose of 12 μg of formoterol- DPI (Foradil®Aerolizer®) and of placebo (pMDI or Aerolizer®) in moderate to severe asthmatic patients. RA/PR/3301/009/03.</citation>
  </reference>
  <reference>
    <citation>Bensch G, Lapidus RJ, Levine BE, Lumry W, Yegen U, Kiselev P, Della Cioppa G. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol. 2001 Jan;86(1):19-27.</citation>
    <PMID>11206232</PMID>
  </reference>
  <reference>
    <citation>Pleskow W, LaForce CF, Yegen U, Matos D, Della Cioppa G. Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial. J Asthma. 2003;40(5):505-14.</citation>
    <PMID>14529100</PMID>
  </reference>
  <reference>
    <citation>Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G; Formoterol in Chronic Obstructive Pulmonary Disease I Study Group. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Sep 1;164(5):778-84.</citation>
    <PMID>11549532</PMID>
  </reference>
  <reference>
    <citation>Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J, Della Cioppa G; Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 2002 Apr;121(4):1058-69.</citation>
    <PMID>11948033</PMID>
  </reference>
  <reference>
    <citation>Mylan Specialty L.P. PERFOROMIST® US Prescribing Information. Morgantown, West Virginia; 2013 Mar.</citation>
  </reference>
  <reference>
    <citation>Gross NJ, Nelson HS, Lapidus RJ, Dunn L, Lynn L, Rinehart M, Denis-Mize K; Formoterol Study Group. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir Med. 2008 Feb;102(2):189-97.</citation>
    <PMID>18363201</PMID>
  </reference>
  <reference>
    <citation>Chiesi Farmaceutici S.p.A. CHF 1535 HFA : BDP + formoterol 100/6 μg pressurized inhalation solution : Common Technical Document. Module 2.5: 8.</citation>
  </reference>
  <reference>
    <citation>Bousquet J, Guenolé E, Duvauchelle T, Vicaut E, Lefrançois G. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients. Respiration. 2005;72 Suppl 1:13-9.</citation>
    <PMID>15915008</PMID>
  </reference>
  <reference>
    <citation>Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993 Mar;16:5-40. Review.</citation>
    <PMID>8499054</PMID>
  </reference>
  <reference>
    <citation>Houghton CM, Langley SJ, Singh SD, Holden J, Monici Preti AP, Acerbi D, Poli G, Woodcock A. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. Br J Clin Pharmacol. 2004 Oct;58(4):359-66.</citation>
    <PMID>15373928</PMID>
  </reference>
  <reference>
    <citation>Juniper EF, Bousquet J, Abetz L, Bateman ED; GOAL Committee. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med. 2006 Apr;100(4):616-21. Epub 2005 Oct 13.</citation>
    <PMID>16226443</PMID>
  </reference>
  <reference>
    <citation>Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J. 2005 Nov;26(5):948-68.</citation>
    <PMID>16264058</PMID>
  </reference>
  <reference>
    <citation>Arievich H, Overend T, Renard D, Gibbs M, Alagappan V, Looby M, Banerji D. A novel model-based approach for dose determination of glycopyrronium bromide in COPD. BMC Pulm Med. 2012 Dec 8;12:74. doi: 10.1186/1471-2466-12-74.</citation>
    <PMID>23217058</PMID>
  </reference>
  <reference>
    <citation>Center for Drug Evaluation and Research Medical Review. Clinical Team Leader Memorandum: Formoterol fumarate inhalation solution 20mcg/2mL; NDA # 22-007: 2007 Mar 15.</citation>
  </reference>
  <reference>
    <citation>Gross NJ, Kerwin E, Levine B, Kim KT, Denis-Mize K, Hamzavi M, Carpenter M, Rinehart M. Nebulized formoterol fumarate: Dose selection and pharmacokinetics. Pulm Pharmacol Ther. 2008 Oct;21(5):818-23. doi: 10.1016/j.pupt.2008.07.002. Epub 2008 Jul 8.</citation>
    <PMID>18655841</PMID>
  </reference>
  <reference>
    <citation>Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999 Oct;14(4):902-7.</citation>
    <PMID>10573240</PMID>
  </reference>
  <reference>
    <citation>Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38.</citation>
    <PMID>16055882</PMID>
  </reference>
  <reference>
    <citation>Hankinson JL, Kawut SM, Shahar E, Smith LJ, Stukovsky KH, Barr RG. Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. Chest. 2010 Jan;137(1):138-45. doi: 10.1378/chest.09-0919. Epub 2009 Sep 9.</citation>
    <PMID>19741060</PMID>
  </reference>
  <reference>
    <citation>Hankinson JL, Bang KM. Acceptability and reproducibility criteria of the American Thoracic Society as observed in a sample of the general population. Am Rev Respir Dis. 1991 Mar;143(3):516-21.</citation>
    <PMID>2001060</PMID>
  </reference>
  <reference>
    <citation>Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O'Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Sullivan SD, Szefler SJ, Thomas MD, Wenzel SE; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009 Jul 1;180(1):59-99. doi: 10.1164/rccm.200801-060ST.</citation>
    <PMID>19535666</PMID>
  </reference>
  <reference>
    <citation>Virchow JC, Backer V, de Blay F, Kuna P, Ljørring C, Prieto JL, Villesen HH. Defining moderate asthma exacerbations in clinical trials based on ATS/ERS joint statement. Respir Med. 2015 May;109(5):547-56. doi: 10.1016/j.rmed.2015.01.012. Epub 2015 Feb 3. Review.</citation>
    <PMID>25676887</PMID>
  </reference>
  <reference>
    <citation>Edwards D, Berry JJ. The efficiency of simulation-based multiple comparisons. Biometrics. 1987 Dec;43(4):913-28.</citation>
    <PMID>3427176</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

